Amgen Inc

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 29 Mar 2019
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

1,375,000€

Financial year: Jan 2018 - Dec 2018

Lobbyists (Full time equivalent)

2.75 Fte (6)

Lobbyists with EP accreditation

4

High-level Commission meetings

3

Lobbying Costs over the years

  • Info

    Amgen Inc

    EU Transparency Register

    42243575237-50 First registered on 07 Feb 2011

    Goals / Remit

    Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

    Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

    Amgen was incorporated in California in 1980 and becamea Delaware corporation in 1987. Amgen has a presence in approximately 100 countries worldwide. It operates in one business segment : human therapeutics.

    Main EU files targeted

    Engage governments and policy makers worldwide on issues important to Amgen to:

    Ensure patients have access to medicines they need
    Provide coverage and reimbursement that reward innovation
    Introduce sound, science-based regulation
    Enable biotechnology research and development (R&D)

    Address

    Head Office
    One Amgen Center Drive
    Thousand Oaks, California 91320-1799
    UNITED STATES
    EU Office
    Telecomlaan 5-7
    Diegem 1831
    BELGIUM
  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    75%1
    50%3
    25%2

    Lobbyists (Full time equivalent)

    2.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    4 accreditations were / are live (in bold) for the selected state of 29 Mar 2019

    Name Start date End Date
    Ms Viktoria TZOUMA 09 Mar 2024 07 Mar 2025
    Mr Nicholas COSENZA 23 Sep 2023 20 Sep 2024
    Mr Vincent MARTICHOU 13 Jul 2023 12 Jul 2024
    Ms Viktoria TZOUMA 02 Feb 2023 02 Feb 2024
    Ms Marie Helene FANDEL 26 Feb 2019 01 Feb 2020
    Mr Douglas GREGORY 24 Jan 2019 24 Jan 2020
    Mr Jamie Nathan WILKINSON 20 Nov 2018 20 Nov 2019
    Mr Vincent MARTICHOU 27 Mar 2018 30 Mar 2019
    Ms Marie Helene FANDEL 16 Feb 2018 16 Feb 2019
    Mr Douglas GREGORY 30 Jan 2018 24 Jan 2019
    Mr Douglas GREGORY 25 Feb 2017 30 Jan 2018
    Ms Marie Helene FANDEL 25 Feb 2017 16 Feb 2018
    Mr Janusz LINKOWSKI 05 Sep 2016 26 Aug 2017
    Mr Douglas GREGORY 14 Jan 2016 13 Jan 2017
    Ms Marie Helene FANDEL 16 Sep 2015 14 Sep 2016
    Mr Janusz LINKOWSKI 05 Sep 2015 03 Sep 2016
    Ms JOANA MARIA GANDARA LEITAO PAIVA 23 Jan 2015 23 Oct 2015
    Mr Douglas GREGORY 23 Jan 2015 14 Jan 2016
    Ms JOANA MARIA GANDARA LEITAO PAIVA 15 Mar 2014 23 Jan 2015
    Mr Douglas GREGORY 01 Mar 2014 23 Jan 2015
    Mr Douglas GREGORY 07 Mar 2013 28 Feb 2014

    Complementary Information

    Following the Transparency Register implementing guidelines, released on 5 October 2015, Amgen has reviewed its financial data regarding activities under the scope of Article 7 of the Inter-Institutional Agreement published in the official journal of 19 September 2014.

    The estimated annual costs arising from activities covered by the Register cover direct and indirect lobbying.

    Amgen calculated our total costs (as per the TR guidelines) by adding up the following elements:
    1. Staff costs (79% of EU Public Affairs expenditures): based on the full-time equivalents (FTEs) already declared. 40 Amgen staff are actively involved; 34 of whom spend less than 25% of their working time.
    2. Office and administrative expenses (5% of EU Public Affairs Expenditures): rent and utilities, supplies and materials.
    3. In-house operational expenditure (2% of EU Public Affairs expenditures): cost of advocacy, PR or public affairs campaigns, marketing and advertising, use of media, organisation of events, publications, etc.
    4. Representation costs (0% of EU Public Affairs expenditures): expenses incurred through taking part in events and meetings.
    5. Outsourced activity costs (less than 1% of EU Public Affairs expenditures): fees for consultants and subcontractors.
    6. Membership and related fees (14% of EU Public Affairs expenditures): fees for joining relevant networks and structures.
    7. Other relevant costs (0% of EU Public Affairs expenditures)

    This new estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    Because there is no de minimus rule, we have tried to identify and report the number of Amgen employees who are covered by the scope of the Transparency Register in the execution of their work responsibilities.

    Person in charge of EU relations

    Mr Douglas Gregory (Executive Director European Union Government Affairs)

    Person with legal responsibility

    Mr Robert Bradway (Chairman and Chief Executive Officer)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Amgen is a member of the following organizations in Brussels:
    American Chamber of Commerce to the EU
    EBE – European Biopharmaceutical Enterprises
    EFPIA – European Federation of Pharmaceutical Industries and Associations
    EPC - European Policy Centre
    Eucope - European Confederation of Pharmaceutical Entrepreneurs
    EuropaBio - The European Association for Bio-industries
    Science Business - brings together industry research and policy

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2018 - Dec 2018

    Lobbying costs for closed financial year

    1,375,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    None

    Communication activities

    None

    Other activities

    None declared

  • Meetings

    Meetings

    3 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 08 Jul 2022 Location call
      Subject pharmaceutical supply chains
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 12 Jun 2020 Location Videoconference
      Subject Videoconference CEO of Amgen and CEO of Teneo (Topic: Preparation of Global Pledging Summit on 27 June)
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      Attending
      • Ursula von der Leyen (President)
      Other Lobbyists
    • Date 17 May 2018 Location Brussels
      Subject Digital Health
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Digital Economy and Society
      Attending
      • Manuel Mateo-Goyet (Cabinet member)
Download this datacard